経皮皮膚パッチ市場：タイプ別、用途別、流通チャネル別、地域別、機会、予測、2017年～2031年

世界の経皮皮膚パッチの市場規模は、予測期間の2024年～2031年に5.20％のCAGRで拡大し、2023年の81億2,000万米ドルから2031年には121億8,000万米ドルに成長すると予測されています。経皮皮膚パッチの市場需要は、神経疾患や心血管疾患などの慢性疾患の有病率の上昇により、予測数年間で飛躍的に成長すると予測されています。

経皮皮膚パッチは新しいドラッグデリバリーシステムです。これらのシステムは、血流への薬剤の制御放出を可能にしながら、皮膚を通して患者に薬剤を送達します。皮膚パッチは患者の皮膚に密着し、浸透促進剤やマイクロニードルなど様々なメカニズムを用いて薬剤から有効成分を皮膚に取り込みます。従来の製剤に比べ、初回通過消化や胃・酵素による薬物分解の回避など、いくつかの利点を示し、患者のコンプライアンスが向上し、副作用が少なく、体内の薬物濃度を常に維持することができます。主な用途としては、疼痛管理、ホルモン補充、禁煙などがあります。

パッチ療法の選択肢は広がりつつあり、より快適で効果的な治療を提供しています。経皮皮膚パッチの需要を牽引しているのは、非侵襲的な薬物送達を好み、患者のコンプライアンスと快適性を向上させることです。さらに、糖尿病や心血管疾患のような慢性疾患の増加は、これらのパッチの必要性を高めており、世界市場の成長に拍車をかけている可能性が高いです。

当レポートでは、世界の経皮皮膚パッチ市場について調査し、市場の概要とともに、タイプ別、用途別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の経皮皮膚パッチ市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 地域別

第5章 北米の経皮皮膚パッチ市場の見通し、2017年～2031年

第6章 欧州の経皮皮膚パッチ市場の見通し、2017年～2031年

第7章 アジア太平洋の経皮皮膚パッチ市場の見通し、2017年～2031年

第8章 南米の経皮皮膚パッチ市場の見通し、2017年～2031年

第9章 中東・アフリカの経皮皮膚パッチ市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要参入企業トップ10の情勢
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Viatris Inc.
  • Samyang Biopharmaceuticals Corp.
  • Agile Therapeutics Inc.
  • Purdue Pharma L.P.
  • Tiekoku Pharma USA Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Luye Pharma Group
  • Zydus Lifesciences Limited.

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 3. Global Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 4. Global Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 5. Global Transdermal Skin Patches Market Share (%), By Region, 2017-2031F
• Figure 6. North America Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 7. North America Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 8. North America Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 9. North America Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 10. North America Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
• Figure 11. United States Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 12. United States Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 13. United States Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 14. United States Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 15. Canada Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 16. Canada Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 17. Canada Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 18. Canada Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 19. Mexico Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 20. Mexico Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 21. Mexico Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 22. Mexico Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 23. Europe Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Europe Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 25. Europe Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 26. Europe Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 27. Europe Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
• Figure 28. Germany Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Germany Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 30. Germany Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 31. Germany Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 32. France Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 33. France Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 34. France Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 35. France Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 36. Italy Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 37. Italy Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 38. Italy Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 39. Italy Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 40. United Kingdom Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 41. United Kingdom Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 42. United Kingdom Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 43. United Kingdom Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 44. Russia Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Russia Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 46. Russia Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 47. Russia Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 48. Netherlands Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 49. Netherlands Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 50. Netherlands Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 51. Netherlands Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 52. Spain Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Spain Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 54. Spain Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 55. Spain Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 56. Turkey Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 57. Turkey Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 58. Turkey Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 59. Turkey Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 60. Poland Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Poland Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 62. Poland Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 63. Poland Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 64. South America Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 65. South America Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 66. South America Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 67. South America Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 68. South America Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
• Figure 69. Brazil Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Brazil Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 71. Brazil Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 72. Brazil Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 73. Argentina Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 74. Argentina Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 75. Argentina Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 76. Argentina Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 77. Asia-Pacific Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 78. Asia-Pacific Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 79. Asia-Pacific Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 80. Asia-Pacific Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 81. Asia-Pacific Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
• Figure 82. India Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 83. India Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 84. India Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 85. India Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 86. China Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 87. China Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 88. China Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 89. China Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 90. Japan Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Japan Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 92. Japan Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 93. Japan Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 94. Australia Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 95. Australia Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 96. Australia Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 97. Australia Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 98. Vietnam Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 99. Vietnam Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 100. Vietnam Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 101. Vietnam Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 102. South Korea Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 103. South Korea Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 104. South Korea Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 105. South Korea Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 106. Indonesia Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 107. Indonesia Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 108. Indonesia Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 109. Indonesia Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 110. Philippines Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 111. Philippines Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 112. Philippines Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 113. Philippines Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 114. Middle East & Africa Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Middle East & Africa Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 116. Middle East & Africa Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 117. Middle East & Africa Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 118. Middle East & Africa Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
• Figure 119. Saudi Arabia Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 120. Saudi Arabia Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 121. Saudi Arabia Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 122. Saudi Arabia Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 123. UAE Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 124. UAE Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 125. UAE Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 126. UAE Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 127. South Africa Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
• Figure 128. South Africa Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
• Figure 129. South Africa Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
• Figure 130. South Africa Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
• Figure 131. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 132. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 133. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global transdermal skin patches market is projected to witness a CAGR of 5.20% during the forecast period 2024-2031, growing from USD 8.12 billion in 2023 to USD 12.18 billion in 2031. The market demand for transdermal skin patches is anticipated to thrive drastically in the forecast years due to the rising prevalence of chronic diseases, such as neurological and cardiovascular diseases.

Transdermal skin patches represent novel drug delivery systems. These systems deliver medicine to a patient through the skin while allowing the controlled release of medication into the bloodstream. The skin patches adhere to a patient's skin and draw active ingredients from the agent into the skin by using various mechanisms, including permeation enhancers or microneedles. It shows some advantages over conventional preparations, such as first-pass digestion and avoidance of gastric/enzymatic drug degradation, with better patient compliance, fewer side effects, and always maintaining its drug levels in the body. Some of the primary applications are pain management, replacement of hormones, and smoking cessation.

Patch therapy options are expanding, offering more comfortable and effective treatments. Demand for transdermal patches is driven by the preference for non-invasive drug delivery, improving patient compliance and comfort. Additionally, the rise in chronic diseases like diabetes and cardiovascular conditions is increasing the need for these patches, likely fueling growth in the global market. For instance, in September 2023, Corium, LLC, a biopharmaceutical company, published data reinforcing that ADLARITY (donepezil transdermal system) is a promising transdermal patch with favorable skin adhesion and tolerability. ADLARITY was approved in March 2022 by the United States Food and Drug Administration (US FDA) for the treatment of mild, moderate, and severe dementia of Alzheimer's disease. Donepezil, an acetylcholinesterase inhibitor and the active ingredient in the oral drug Aricept is the most prescribed Alzheimer's dementia medication in the United States.

Increased Demand for Non-Invasive Delivery Brings Market Growth

Rising demand for non-invasive delivery methods significantly drives growth in the transdermal skin patch market. The healthcare sector is increasingly focused on pain-free drug administration, appealing to patients seeking less invasive therapies. Today's patients prefer options that minimize discomfort, avoiding needles or surgical procedures. The healthcare landscape appeals to less painful drug administrations. Patients these days would want therapies that minimize the discomfort and avoid going through some form of surgery or sticking needles into their bodies. These alternatives include transdermal skin patches, comforted by ease of application because they can be self-administered at home without the need for professional assistance. The reasons are particularly pertinent to the case of chronic diseases that require long-term treatment. Patients prefer painless and user-friendly regimens. In addition, non-invasive delivery is less likely to cause complications such as infection or allergic reactions associated with injections. As the healthcare system continues to draw more focus on pain control and patient compliance, there is likely to be greater demand for non-invasive delivery systems that enhance compliance, further fueling the innovation of drug delivery technologies. For instance, in October 2023, Luye Pharma Group received approval for Rivastigmine transdermal patch from China's National Medical Products Administration (NMPA). The patches are proven to be a promising treatment for symptomatic mild to moderate Alzheimer's disease (AD) and have been widely adopted in Europe.

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a major growth driver for the transdermal skin patch market, which usually requires long-term management and consistent therapeutic intervention; the growth rate for the transdermal skin patches market is very high. For example, diabetes, hypertension, and chronic pain disorders require precise and effective delivery systems to enhance compliance among patients and ensure optimal health outcomes. The convenience offered through sustained-release medication in transdermal patches is a great solution, as it maintains constant levels of drugs in the bloodstream and decreases the dosing frequency. This is especially attractive to patients on multiple medications or on complex regimens. As the aging population becomes more susceptible to chronic diseases, demand for innovative delivery systems like transdermal skin patches. These patches effectively manage chronic conditions while prioritizing patient comfort and compliance. This trend is expected to drive substantial transdermal skin patch market growth.

A report published by the Shanghai Municipal People's Government highlights chronic disease population among the elderly as a major public health issue in China. The report stated that in 2023, among China's 190 million elderly population, 75% are suffering from at least one chronic condition, while 43% are managing two or more chronic diseases. This underlines the urgent need for health strategies focused on chronic disease management in China's aging population.

Multi-Layer Drug-in-Adhesive Patches to Dominate the Transdermal Skin Patches Market

The multi-layer drug-in-adhesive patches segment is anticipated to assert strong dominance in the transdermal skin patches market. The drug-in-adhesive patches combine various layers of drug and adhesive for prolonged delivery of active ingredients and offer active ingredient stability with less skin irritation, thereby improving patient comfort and compliance. On the rise of personalized treatment options and efficient management of chronic conditions, the versatility and efficiency offered by multilayer drug-in-adhesive patches are ideal for choice among patients and healthcare providers. These are the major factors driving the growth of the transdermal skin patches market.

Moreover, technological advancements and new product launches will further fuel the segment's growth in the market. For instance, in September 2023, Zydus Lifesciences Limited received approval from the United States Food and Drug Administration for Norelgestromin and Ethinyl Estradiol Transdermal System. These patches provide combination hormone medication and are used to prevent pregnancy.

North America Dominates Transdermal Skin Patches Market

North American region is anticipated to dominate the transdermal skin patches market for several reasons, including advanced healthcare infrastructure, a high level of awareness, and the most significant investment in research and development in the region. The strong pharmaceutical sector in the region has played an important role in the innovation and commercialization of new transdermal delivery systems to target the ever-growing demand for efficient and easy forms of treatment. The prevalence of chronic diseases like diabetes and cardiovascular conditions has also pushed the development of safe methods of delivering medication, thereby improving patient compliance. For instance, in August 2024, Zydus Lifesciences Limited received US FDA approval for its Scopolamine Transdermal System, a patch indicated to prevent nausea and vomiting associated with anesthesia, opioid medications, surgery, and motion sickness. The Scopolamine Transdermal System achieved annual sales of USD 69.6 million in the U.S.

Future Market Scenario (2024-2031F)

The future scenario for transdermal skin patches is promising, driven primarily by ongoing technological advancements and evolving healthcare needs. Growing demand for non-invasive drug delivery methods, such as micro needle patches and smart delivery systems, is expected to increase the effectiveness and flexibility of transdermal therapies. The increasing prevalence of chronic diseases and the aging population are likely to drive demand for long-acting products that help improve patient compliance as well as outcomes from therapies. Markets are set to expand into other areas, such as pain management, hormone therapies, and vaccinations, hence driving the growth of the transdermal patches market.

For instance, in January 2024, Starton Therapeutics Inc., a biotechnology company, launched STARSILON, a transdermal patch delivery platform. This adhesive transdermal technology enables continuous, low-dose delivery of various molecules, including those targeting oncology, inflammation, and central nervous system (CNS)conditions. The platform aims to enhance efficacy, reduce toxicity, and improve patient tolerance, opening new opportunities for expanded therapeutic applications.

Key Players Landscape and Outlook

The global transdermal skin patches market is highly competitive, with leading and emerging players vying to capture the elevating opportunities. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of market players' products. The market also fosters several smaller players, which operate through collaborations with other players to cater to a larger market.

In August 2024, Agile Therapeutics, Inc. completed the acquisition of Indus Pharma, S.L., a global pharmaceutical group based in Spain. Agile Therapeutics specializes in addressing unmet women's healthcare needs for contraception. Their lead product is Twirla, a prescription contraceptive that delivers levonorgestrel and ethinyl estradiol through a non-daily transdermal patch.

In September 2023, Yaral Pharma Inc. (Yaral Pharma), a subsidiary of Institute Biochimique SA (IBSA), launched Lidocaine Patch 5% for the treatment of pain management and inflammation.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Transdermal Skin Patches Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Single-Layer Drug-in-Adhesive Patches
    • 4.2.1.2. Multi-Layer Drug-in-Adhesive Patches
    • 4.2.1.3. Matrix Patches
    • 4.2.1.4. Microneedle Patches
    • 4.2.1.5. Others
  • 4.2.2. By Application
    • 4.2.2.1. Pain Management
    • 4.2.2.2. Hormonal Therapy
    • 4.2.2.3. Cardiovascular Disease
    • 4.2.2.4. Neurological Disorder
    • 4.2.2.5. Smoking Reduction and Cessation Aid
    • 4.2.2.6. Others
  • 4.2.3. By Distribution Channel
    • 4.2.3.1. Hospital Pharmacies
    • 4.2.3.2. Retail Pharmacies
    • 4.2.3.3. Online Pharmacies
    • 4.2.3.4. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Type
  • 4.3.2. By Application
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. North America Transdermal Skin Patches Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Single-layer Drug-in-adhesive Patches
    • 5.2.1.2. Multi-layer Drug-in-adhesive Patches
    • 5.2.1.3. Matrix Patches
    • 5.2.1.4. Microneedle Patches
    • 5.2.1.5. Others
  • 5.2.2. By Application
    • 5.2.2.1. Pain Management
    • 5.2.2.2. Hormonal Therapy
    • 5.2.2.3. Cardiovascular Disease
    • 5.2.2.4. Neurological Disorder
    • 5.2.2.5. Smoking Reduction and Cessation Aid
    • 5.2.2.6. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
    • 5.2.3.4. Others
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Transdermal Skin Patches Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Single-layer Drug-in-adhesive Patches
        • 5.3.1.2.1.2. Multi-layer Drug-in-adhesive Patches
        • 5.3.1.2.1.3. Matrix Patches
        • 5.3.1.2.1.4. Microneedle Patches
        • 5.3.1.2.1.5. Others
      • 5.3.1.2.2. By Application
        • 5.3.1.2.2.1. Pain Management
        • 5.3.1.2.2.2. Hormonal Therapy
        • 5.3.1.2.2.3. Cardiovascular Disease
        • 5.3.1.2.2.4. Neurological Disorder
        • 5.3.1.2.2.5. Smoking Reduction and Cessation Aid
        • 5.3.1.2.2.6. Others
      • 5.3.1.2.3. By Distribution Channel
        • 5.3.1.2.3.1. Hospitals Pharmacies
        • 5.3.1.2.3.2. Retail Pharmacies
        • 5.3.1.2.3.3. Online Pharmacies
        • 5.3.1.2.3.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Transdermal Skin Patches Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Transdermal Skin Patches Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Transdermal Skin Patches Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Transdermal Skin Patches Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Teva Pharmaceuticals Industries Ltd.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. Novartis AG
  • 20.3.3. Johnson & Johnson Services, Inc.
  • 20.3.4. Viatris Inc.
  • 20.3.5. Samyang Biopharmaceuticals Corp.
  • 20.3.6. Agile Therapeutics Inc.
  • 20.3.7. Purdue Pharma L.P.
  • 20.3.8. Tiekoku Pharma USA Inc.
  • 20.3.9. Hisamitsu Pharmaceutical Co., Inc.
  • 20.3.10. Luye Pharma Group
  • 20.3.11. Zydus Lifesciences Limited.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer